Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024 - 08/04/25
, Hannah C. Moore c, e, Peter C. Richmond c, d, f, g, Avram Levy i, j, Lana Bell k, Catherine Pienaar a, c, Joanne Harvey a, c, Caroline Finucane a, c, Erin van der Helder a, c, Lauren Bloomfield h, l, Allen Cheng m, n, Paul Effler d, h, Christopher C. Blyth a, c, d, jSummary |
Background |
Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country’s first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season. This study describes the effectiveness of nirsevimab against RSV hospitalisation over a single epidemic season.
Methods |
Between April and October 2024, children hospitalised with laboratory-confirmed RSV-associated acute respiratory infection (ARI) and test-negative controls were enrolled from three hospitals in WA. Demographic variables, medical risk factors, symptoms and outcomes were assessed. Nirsevimab effectiveness in preventing RSV-associated hospitalisation was estimated.
Results |
Over 7 months, 284 children eligible for nirsevimab were enrolled including 184 RSV positive cases and 100 controls. Coverage of nirsevimab in RSV cases was 22.8% and 60.0% in controls. The overall adjusted effectiveness of nirsevimab against RSV-associated ARI hospitalisation was 88.2% (95% CI: 73.5, 94.7). RSV infection occurred in 42 (22.8%) children who had received nirsevimab; there was no significant difference in RSV illness severity among those immunised and unimmunised.
Conclusion |
Nirsevimab was highly effective at preventing RSV-associated ARI hospitalisation in young children in the southern hemisphere.
Summary |
This study is the first Australian study to provide nirsevimab effectiveness estimate against RSV hospitalisation over a single epidemic season. The adjusted estimate of nirsevimab effectiveness against RSV-associated ARI hospitalisation was 88.2%, similar to those reported from Northern Hemisphere countries.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years. |
• | Nirsevimab is a new long-acting monoclonal antibody for prevention of RSV infection. |
• | First Australian study to provide nirsevimab effectiveness estimate over a single epidemic season. |
• | The adjusted estimate of nirsevimab effectiveness against RSV-associated hospitalisation was 88.2%. |
• | This is similar to that reported in Northern Hemisphere countries. |
Keywords : Respiratory syncytial virus, Nirsevimab, Effectiveness, Hospitalisation, Real-world, Children, Immunisation
Plan
Vol 90 - N° 4
Article 106466- avril 2025 Retour au numéro
Article précédent
- Global epidemiology, seasonality and climatic drivers of the four human parainfluenza virus types
- Yi Song, Yu-Nong Gong, Kuan-Fu Chen, David K. Smith, Hassan Zaraket, Seweryn Bialasiewicz, Sarah Tozer, Paul KS Chan, Evelyn SC Koay, Hong Kai Lee, Kok Keng Tee, Pieter LA Fraaij, Lance Jennings, Matti Waris, Hidekazu Nishimura, Aripuana Watanabe, Theo Sloots, Jen Kok, Dominic E. Dwyer, Marion PG Koopmans, David W. Smith, Julian W. Tang, Tommy TY Lam, on behalf of the INSPIRE consortium
- Direct-acting antiviral treatment outcomes in people infected with endemic compared to epidemic hepatitis C virus subtypes in England
- Laura T. Phillips, Daniel Bradshaw, Simon Packer, Ruth Simmons, Rare HCV Subtypes Group, William M. Rosenberg, Caroline A. Sabin, Jean L. Mbisa
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?